PROTEOSTASIS THERAPEUTICS, INC. News (NASDAQ:PTI)

DateTimeSource
Headline
09/28/20167:30AMGLOBEProteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Boa...
CAMBRIDGE, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced the appointment of Naimish Patel, M.D., C.M., and... More...>>
09/22/20167:30AMGLOBEProteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Confer...
CAMBRIDGE, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF), today announced that company scientists will present data from... More...>>
09/15/20166:30PMGLOBEProteostasis Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that Meenu Chhabra, president and chief executive... More...>>
09/14/20164:03PMGLOBEProteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the closing of its follow-on public offering of... More...>>
09/09/20167:30AMGLOBEProteostasis Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the pricing of its follow-on public offering of 5,000,000... More...>>
08/11/20167:45AMGLOBEProteostasis Therapeutics Issues Mid-Year Corporate Update on Cystic Fibrosis Pipeline Programs
CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced a mid-year corporate update highlighting the company’s... More...>>
08/08/201610:57AMGLOBEProteostasis Therapeutics Achieves Preclinical Milestone in Astellas Pharma Collaboration
CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, today announced that it has successfully completed a key preclinical milestone... More...>>
08/08/201610:54AMGLOBEProteostasis Therapeutics Announces Key Leadership Appointments
CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced the appointment of James M. DeTore as chief financial... More...>>
03/30/20162:08PMGLOBEProteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for...
CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF), today announced new preclinical data on the company’s first-in-class... More...>>
03/28/20167:30AMGLOBEProteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Scie...
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF), today announced two abstracts will be presented during the flash... More...>>
02/18/20166:30AMGLOBEProteostasis Therapeutics, Inc. Announces Closing of Initial Public Offering
CAMBRIDGE, Mass., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share. All of the shares sold in the offering were offered by Proteostasis Therapeutics, Inc. The company’s... More...>>
02/11/20161:10PMDJNDrug Developers Slide in Trading Debut
Shares of drug developers Proteostasis Therapeutics Inc. and AveXis Inc. fell sharply on their first day of trading, highlighting the difficulty initial public offerings have faced this year. Proteostasis and AveXis are only the third and fourth IPOs since Dec. 17. There were no U.S. IPOs in January, the first monthlong... More...>>
02/11/20168:24AMGLOBEProteostasis Therapeutics Inc. (Nasdaq: PTI) to Ring the Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, Feb. 11, 2016 (GLOBE NEWSWIRE) -- What: Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a company developing novel therapeutics that regulate protein biosynthesis, folding, trafficking and clearance to improve outcomes for patients with protein processing diseases, will visit the Nasdaq MarketSite in Times... More...>>
02/11/20167:21AMGLOBEProteostasis Therapeutics, Inc. Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Proteostasis... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160929 05:04:20